Medivir, Novartis Resolve Dispute Over Partially Overlapping Patents
The two companies penned a two-way license agreement to settle the case, they said. Under the agreement, Medivir will have exclusive rights to topical combination products containing the antiviral agent acyclovir or omaciclovir, Medivir's antiviral substance.
In turn, Novartis is granted a non-exclusive licence to certain antiviral combination products such as penciclovir, while Medivir will retain the...
To view the full article, register now.